The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study).
 
Tanya Siddiqi
Consulting or Advisory Role - Juno Therapeutics
Speakers' Bureau - Pharmacyclics/Janssen; Seagen
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Genentech (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Jeremy S. Abramson
Consulting or Advisory Role - Celgene; Genentech/Roche; Gilead Sciences; Novartis; Seagen
Research Funding - Celgene (Inst); genentech (Inst); Millennium (Inst); Seagen (Inst)
 
Maria Lia Palomba
Honoraria - Juno Therapeutics (I)
Consulting or Advisory Role - Merck; Pharmacyclics
 
Leo I. Gordon
Patents, Royalties, Other Intellectual Property - Zylem
Other Relationship - Gilead Sciences
 
Matthew Alexander Lunning
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Genentech; Gilead Sciences; Juno Therapeutics; Pharmacyclics; Seagen; TG Therapeutics
 
Jon E. Arnason
Consulting or Advisory Role - Gilead Sciences; Regeneron
 
Michael Wang
Honoraria - Acerta Pharma; Janssen
Consulting or Advisory Role - Acerta Pharma; Janssen; Pharmacyclics
Research Funding - Acerta Pharma; Asana Biosciences; BeiGene; Celgene; Janssen; Juno Therapeutics; Kite, a Gilead company; Novartis
 
Andres Forero-Torres
Speakers' Bureau - Seagen
Research Funding - Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Seagen (Inst); Syndax (Inst); TRACON Pharma (Inst)
 
David G. Maloney
Research Funding - Juno Therapeutics (Inst)
 
Mark Heipel
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
Research Funding - Juno Therapeutics
 
Jeffrey Smith
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
Travel, Accommodations, Expenses - Juno Therapeutics
 
William Brown
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
Travel, Accommodations, Expenses - Juno Therapeutics
 
Mandana Karimi
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
 
Benhuai Xie
Employment - Astellas Pharma (I); Takeda
 
Daniel Li
Employment - Juno Therapeutics
Stock and Other Ownership Interests - CTI; Gilead Sciences; Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
 
Tina Albertson
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
 
Jacob Garcia
Employment - Amgen; Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
Travel, Accommodations, Expenses - Juno Therapeutics
 
Kedar Dave
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
Travel, Accommodations, Expenses - Juno Therapeutics
 
Todd DeVries
Employment - CTI BioPharma Corp; Juno Therapeutics
Stock and Other Ownership Interests - CTI BioPharma Corp; Juno Therapeutics
Consulting or Advisory Role - KinDex
 
Claire Sutherland
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
Travel, Accommodations, Expenses - Juno Therapeutics